AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 14623548
Drug: Low doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low doses of aromatase inhibitors
Trial: 10714753
Drug: GH therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH therapy (somatotropin, 0.222 mg/kg/week, divided into 3 doses each week)
Trial: 8928847
Drug: L-NMMA (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-NMMA (3 mg/kg in 10 ml saline)
Trial: 4058956
Drug: i.v. naloxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. naloxone (0.04 mg/kg)
Trial: 30241688
Drug: SL edaravone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SL edaravone 30 mg
Trial: 30241688
Drug: IV edaravone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV edaravone 30 mg infusion
Trial: 30241688
Drug: Both SL
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both SL and IV administration
Trial: 15164501
Drug: Long-term morphine-clopheline
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term morphine-clopheline epidural analgesia
Trial: 15164501
Drug: Conventional analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional analgesia (intravenous injection of morphine)
Trial: 8989246
Drug: GH therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH therapy at doses of 0.6 and 1.2 IU/day
Trial: 2955253
Drug: Low MW
RxNorm normalized name: low-substituted hydroxypropyl cellulose (11% hydroxypropyl; 100000 MW)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low MW heparin (Kabi 2165) administered as 5000 or 10,000 anti-factor Xa units, s.c., half an hour prior to dialysis
Trial: 2955253
Drug: Single bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single bolus injection of 5000 anti-factor Xa units of low MW heparin given i.v.
Trial: 2955253
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of low MW heparin at 5000 anti-factor Xa units bolus plus 1500 anti-factor Xa units/h
Trial: 2955253
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of low MW heparin at approximately 4000 anti-factor Xa units bolus plus 750 anti-factor Xa units/h
Trial: 25013996
Drug: Low-dose GH
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose GH (LGH) therapy
Trial: 22699446
Drug: Purified chick
RxNorm normalized name: rabies vaccine, purified chick embryo cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purified chick embryo cell (PCECV) rabies vaccine
Trial: 22699446
Drug: Purified verocell
RxNorm normalized name: RAYON,PURIFIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purified verocell rabies vaccine (PVRV)
Trial: 15676050
Drug: Sublingual fentanyl
RxNorm normalized name: fentanyl Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual fentanyl 400 microg
Trial: 20015921
Drug: Sublingual fentanyl
RxNorm normalized name: fentanyl Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual fentanyl 100 and 200 microg
Trial: 18809612
Drug: Hypnosis intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hypnosis intervention (five weekly sessions)
Trial: 15757817
Drug: Paromomycin sulfate
RxNorm normalized name: Paromomycin Sulfate
DrugBank: Paromomycin (DB01421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paromomycin sulfate ointment (15% in urea) applied twice daily for 20 days
Trial: 15757817
Drug: Meglumine antimonate
RxNorm normalized name: meglumine antimonate
DrugBank: Meglumine antimoniate (DB13732)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meglumine antimonate (1 ml intradermally every other day for 20 days)
Trial: 11828262
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E (dl‐alpha‐tocopherol) 1000 mg/day for 3 months
Trial: 10049268
Drug: Fasting conditions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasting conditions (twice)
Trial: 10049268
Drug: Antacids (aluminum-magnesium)
RxNorm normalized name: ALUMINUM/MAGNESIUM HYDROXIDE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antacids (aluminum-magnesium)
Trial: 7589655
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist (GnRH-a) initiated in early follicular phase
Trial: 7589655
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist (GnRH-a) initiated in midluteal phase
Trial: 7589655
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist (GnRH-a) initiated in late luteal phase
Trial: 31701170
Drug: Pembrolizumab monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab monotherapy (for selected patients with PD-L1 CPS ≥1 and ≥20)
Trial: 17868011
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment over a 6-week course
Trial: 17868011
Drug: Prophylactic drug
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic drug treatment over a 6-month period
Trial: 8972953
Drug: Topical anaesthetic
RxNorm normalized name: Topical anaesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anaesthetic EMLA cream
Trial: 1479198
Drug: Combined hyperthermia
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined hyperthermia (HT) and radiation therapy (XRT)
Trial: 6428504
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of 35% carbon dioxide and 65% oxygen
Trial: 6428504
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of 35% carbon dioxide and 65% oxygen preceded by 60 mg propranolol
Trial: 25613235
Drug: Prolonged Exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged Exposure Therapy
Trial: 9540025
Drug: Miglitol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Miglitol (50 or 100 mg t.i.d.)
Trial: 8294388
Drug: Combined SSRI
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined SSRI (sertraline or fluvoxamine) with moclobemide
Trial: 8294388
Drug: Moclobemide (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moclobemide (150 to 800 mg/day) with sertraline (25 to 200 mg/day)
Trial: 8294388
Drug: Moclobemide (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moclobemide (150 to 800 mg/day) with fluvoxamine (50 to 200 mg/day)
Trial: 2660873
Drug: Sultamicillin (375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sultamicillin (375 mg)
Trial: 2660873
Drug: Trimethoprim/sulfamethoxazole (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim/sulfamethoxazole (160 mg/800 mg)
Trial: 4261553
Drug: Spectinomycin 2
RxNorm normalized name: spectinomycin 2 g intramuscular powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spectinomycin 2 g
Trial: 4261553
Drug: Spectinomycin 4
RxNorm normalized name: spectinomycin 4000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spectinomycin 4 g
Trial: 24885005
Drug: Video-based feedback
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Video-based feedback of public oral presentations
Trial: 24885005
Drug: Classical oral
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Classical oral presentations without feedback (Control)
Trial: 17962424
Drug: Carvedilol controlled-release
RxNorm normalized name: carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carvedilol controlled-release 40 mg with ethanol (approximately 38 g)
Trial: 17962424
Drug: Carvedilol controlled-release
RxNorm normalized name: carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carvedilol controlled-release alone
Trial: 17962424
Drug: Carvedilol controlled-release
RxNorm normalized name: carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carvedilol controlled-release with ethanol 2 hours after administration
Trial: 17962424
Drug: Carvedilol controlled-release
RxNorm normalized name: carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carvedilol controlled-release alone or with ethanol
Trial: 16236169
Drug: Steroid-naïve atopic
RxNorm normalized name: Atopica
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid-naïve atopic asthmatic children
Trial: 16236169
Drug: Atopic asthmatic
RxNorm normalized name: Atopica
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atopic asthmatic children receiving inhaled corticosteroids
Trial: 12404872
Drug: 10 ml
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml of antivenom
Trial: 12404872
Drug: 2 to
RxNorm normalized name: T2 toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 to 5 ml of antivenom
Trial: 12404872
Drug: No antivenom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antivenom administration
Trial: 2697725
Drug: 1% fusidic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% fusidic acid viscous eye drops, instilled twice daily for 7 days
Trial: 2697725
Drug: rifamycin eye
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rifamycin eye drops, four times daily for 7 days
Trial: 12484
Drug: Oxypertine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxypertine (10 mg every 12 hours, 20 mg daily)
Trial: 7104467
Drug: Conventional 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional 4 mg tablet administered every 6 hours
Trial: 7104467
Drug: Controlled release
RxNorm normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled release 8 mg barrier coated-bead capsule administered every 12 hours
Trial: 7104467
Drug: Controlled release
RxNorm normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled release 8 mg repeat action tablet administered every 12 hours
Trial: 25853935
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (levosimendan + nesiritide)
Trial: 23200590
Drug: Domiciliary non-invasive
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domiciliary non-invasive ventilation in addition to long-term oxygen therapy (LTOT)
Trial: 15342839
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) treatment, 33 microg/kg/day for 3 years
Trial: 11180040
Drug: ADL 8-2698
RxNorm normalized name: Adlyxin
DrugBank: Lixisenatide (DB09265)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: ADL 8-2698 (4 mg) with intravenous morphine (0.05 mg x kg(‐1))
Trial: 11180040
Drug: Intravenous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous morphine (0.05 mg x kg(‐1))
Trial: 11180040
Drug: ADL 8-2698
RxNorm normalized name: Adlyxin
DrugBank: Lixisenatide (DB09265)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: ADL 8-2698 (4 mg) with intravenous morphine (0.15 mg/kg)
Trial: 9895052
Drug: Mechanical lithotripsy
RxNorm normalized name: PIPERONYL BUTOXIDE TECHNICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mechanical lithotripsy (ML)
Trial: 8043892
Drug: Continuous subcutaneous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous subcutaneous insulin infusion for improvement of glycaemic control
Trial: 8043892
Drug: Reduced insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced insulin dose
Trial: 8043892
Drug: Increased insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Increased insulin dose
Trial: 31178499
Drug: Medication adherence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication adherence for phosphate binders
Trial: 31178499
Drug: Medication adherence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication adherence for antidiabetic medications
Trial: 31178499
Drug: Reason for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reason for missed dose
Trial: 31178499
Drug: Patient preference
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient preference for oral medication (mental burden present)
Trial: 31178499
Drug: Patient preference
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient preference for oral medication (no mental burden)
Trial: 31178499
Drug: Patient preference
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient preference for oral medication (neither)
Trial: 31178499
Drug: Reduction of
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduction of mental burden by eliminating 1 medication
Trial: 26433819
Drug: Dabrafenib (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dabrafenib (150 mg twice-daily) and Trametinib (2 mg once-daily)
Trial: 26433819
Drug: Vemurafenib (960
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vemurafenib (960 mg twice-daily)
Trial: 21863678
Drug: Mometasone spray
RxNorm normalized name: mometasone Metered Dose Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mometasone spray
Trial: 21863678
Drug: NSS (Normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSS (Normal Saline Solution)
Trial: 19856872
Drug: Complex compound
RxNorm normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complex compound of Cu(II) (dinitrate (V) di (3,4,5‐trimethyl‐N1‐pyrazol‐kappaN2) copper (II))
Trial: 19856872
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no Cu(II) compound)
Trial: 16960473
Drug: Citalopram (a
RxNorm normalized name: citalopram (as citalopram hydrobromide)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (a selective serotonin reuptake inhibitor)
Trial: 16960473
Drug: Buspirone (5-HT1a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone (5-HT1a receptor-specific challenge)
Trial: 8818855
Drug: Comparator agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparator agents (amoxycillin, co-amoxiclav, cefixime, cefaclor, clarithromycin, erythromycin, penicillin V, cloxacillin, or roxithromycin)
Trial: 23410792
Drug: Comparator agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparator agents
Trial: 2004477
Drug: GHRH (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHRH (100 micrograms i.v. in bolus) plus rhEPO (40 U/kg in constant infusion for 30 min)
Trial: 18495964
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron sucrose (100 mg of elemental iron)
Trial: 18495964
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron sucrose (various doses ranging from 20 to 500 mg)
Trial: 8555470
Drug: High-dose cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cyclophosphamide (45 mg/kg/d for 4 consecutive days)
Trial: 6823889
Drug: Consideration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consideration of contamination iron in iron absorption measurements
Trial: 23144438
Drug: Preperitoneal continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preperitoneal continuous wound infusion (CWI) with ropivacaine 0.2% at 10 mL/h for 48 hours
Trial: 23144438
Drug: Continuous epidural
RxNorm normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous epidural infusion (CEI) with ropivacaine 0.2% at 10 mL/h for 48 hours
Trial: 23144438
Drug: Preperitoneal continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preperitoneal continuous wound infusion (CWI)
Trial: 18928218
Drug: Mitomycin C
RxNorm normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitomycin C (1 mg/ml applied at the site of discectomy for 5 minutes)
Trial: 16086983
Drug: Internet-administered self-help
RxNorm normalized name: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Internet-administered self-help plus minimal therapist contact via e-mail
Trial: 16086983
Drug: Traditional individual
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional individual cognitive behaviour therapy
Trial: 8349938
Drug: Methacholine nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methacholine nasal challenge (1 to 25 mg)
Trial: 3770869
Drug: Oral calcium
RxNorm normalized name: Coral Calcium
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral calcium supplementation (1 g/day)
Trial: 22767199
Drug: Intratympanic steroids
RxNorm normalized name: ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intratympanic steroids (4 injections of 0.3 ml dexamethasone at 8 mg/ml and 0.2 ml hyaluronic acid 0.2%)
Trial: 22767199
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (prednisolone, hydroxyethyl starch, pentoxyfylline)
Trial: 17963825
Drug: Monthly fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Monthly fluorouracil (1000 mg/m2/day i.v. for 5 days) plus cisplatin (20 mg/m2/day i.v.)
Trial: 17963825
Drug: Weekly cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly cisplatin (30 mg/m2 i.v.)
Trial: 17963825
Drug: Monthly fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Monthly fluorouracil plus cisplatin
Trial: 31164277
Drug: Weekly cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly cisplatin
Trial: 9760148
Drug: mini‐ICE/ICE chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mini‐ICE/ICE chemotherapy
Trial: 9760148
Drug: 5 +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 + 2/7 + 3 chemotherapy
Trial: 25832443
Drug: 400 mg/day
RxNorm normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg/day of DHA supplementation for two weeks
Trial: 12743539
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus 5‐methoxytryptamine (5‐MTT) 1 mg/day orally
Trial: 12743539
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (cisplatin plus etoposide)
Trial: 3978014
Drug: EMLA 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EMLA 5% cream (Eutectic Mixture of Local Anaesthetics)
Trial: 30880074
Drug: Serenoa repens
RxNorm normalized name: Serenoa Repens Fruit
DrugBank: Saw palmetto (DB14360)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serenoa repens extract (320 mg)
Trial: 30281182
Drug: 100% oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100% oxygen with a bolus of 3 μg/kg fentanyl (group FENTANYL)
Trial: 25250780
Drug: Testoviron depot
RxNorm normalized name: Primoteston Depot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testoviron depot (i.m.: 100 mg/10 days)
Trial: 25250780
Drug: Testosterone gel
RxNorm normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone gel (50 mg/die)
Trial: 25250780
Drug: Testosterone undecanoate
RxNorm normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone undecanoate (i.m.: 1,000 mg every 6 weeks for the first 6 weeks and then every 12 weeks)
Trial: 22765768
Drug: Ivabradine 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivabradine 10 mg alone
Trial: 22765768
Drug: Ivabradine 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivabradine 10 mg after pre-treatment with phenytoin 150 mg
Trial: 16220082
Drug: INH-A21 750
RxNorm normalized name: COXSACKIEVIRUS A21
DrugBank: Gebasaxturev (DB17296)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INH-A21 750 mg/kg
Trial: 7589766
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg sustained-release isradipine
Trial: 7589766
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg lacidipine
Trial: 2289389
Drug: Tetracycline (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetracycline (250 mg, five-day course every six hours)